Vaccines

The French firm will always ‘defend with evidence’ the positive impact of vaccination, ‘irrespective of who is in office,’ the French firm’s CEO has declared.

A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.

Intranasal H5N1 vaccine experts discuss Phase I data, mucosal immunity, BARDA/NIH funding realities and how BlueWillow Biologics' NanoVax platform could strengthen global pandemic flu preparedness and respiratory defenses.

A year after Valneva entered a tech transfer agreement for its chikungunya vaccine with Serum Institute, the deal has been called off. Regulatory approvals for the vaccine in Asia are yet to be obtained and the biologics license for Ixchiq remains suspended in the US. What happens hereon?

Anvisa, the Brazilian medicines regulator, has published a new Q&A document relating to clinical research requirements. Meanwhile, the regulator’s new innovation committee, set up to monitor and evaluate innovative products, has set out its key priority areas.

Biological E joins the ranks of Pfizer, GSK and Serum with WHO prequalification for its pneumococcal vaccine. As WHO's purchase data for Serum’s PSV10 indicate significant opportunity, Scrip spoke to Biological E on supply readiness and its application for exemption from price control in India

Reduced immunization rates in the US marred the results of both GSK and Merck, but with Merck’s biggest drug approaching its loss of exclusivity, lower vaccine sales and sluggish new product revenues spooked investors. GSK left more room for optimism.

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

CSL Limited said during its annual meeting that with US influenza vaccination rates down 12%-14%, it will delay the separation of its vaccine business Seqirus beyond the end of financial year 2026.

Dupixent revenues were a record €4.16bn but the “negative buzz around vaccines” is hurting flu sales, according to chief financial officer François Roger.

The company is discontinuing congenital CMV development for its mRNA-1647 vaccine but still running a Phase II trial in bone marrow transplant patients.

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.